Want to see HTFL full AI Analyst Report?

EarningsQ2 2026 Earnings Report

HeartFlow, Inc. (HTFL) Q2 2026 Earnings Report

94 Followers

Previous Report: Q1 2026

HTFL Q2 2026 EPS Results

Actual EPS-$0.07

Consensus EPS-$0.13

Beat/MissBeat by +$0.06

One Year Ago EPS-$0.06

HTFL Q2 2026 Revenue Results

Actual Revenue$64.08M

Expected Revenue$56.63M

Beat/MissBeat by +$7.45M

YoY Revenue Growth―

Earnings Announcement Details

QuarterQ2 2026

Date08/13/2026

TimeAfter Close

Conference CallThursday, August 13, 2026

HTFL Upcoming Earnings

HeartFlow, Inc.'s next earnings date is estimated for November 18, 2026, based on past reporting schedules.

Q2 2026 Earnings Call Audio

HTFL Q2 2026 Earnings Call

0:00 / 0:00

Q2 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2026 Earnings Call Summary

Q2 2026

Earnings Call Date:Aug 13, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call emphasized strong top-line momentum (48% YoY Q2 revenue growth), significant gross-margin expansion (770 bps YoY) and raised full-year guidance, supported by accelerating Plaque adoption, durable FFRCT utilization, a rich clinical evidence base, and a clear R&D pipeline. Offsets include remaining GAAP losses, early-stage Plaque penetration relative to its long-term potential, ongoing litigation, and pricing/ASP dynamics that could moderate in 2027. On balance, operational and financial progress, upgraded guidance, and a solid cash position outweigh the near-term risks.

Company Guidance

Management raised full‑year 2026 revenue guidance to $246M–$250M (40%–42% YoY) and increased Plaque revenue guidance to $29M–$31M with roughly 1,250 Plaque‑activated accounts expected by year‑end; Q2 revenue was $64.1M (up 48% YoY), U.S. revenue $59.6M (up 51%) including $7.8M of Plaque, OUS $4.5M, and total global reads/cases ~84,491 (up 74%). Q2 non‑GAAP gross margin was 83.3% (vs 75.6% LY, +770 bps) and full‑year non‑GAAP gross margin guidance was raised to ~82% (mid‑term target 85%), with midpoint revenue implying ~50% YoY gross profit growth. Operating leverage improved: non‑GAAP OpEx were 96% of revenue (vs 102% LY), non‑GAAP operating loss $7.9M (vs $11.5M), non‑GAAP net loss $5.8M or $0.07/sh (vs $17.6M or $2.79), GAAP net loss $15.7M or $0.18/sh, weighted shares 86.4M, and cash + investments $246.8M. Management reiterated plans for cash‑flow profitability by mid‑2028 and outlined R&D and clinical plans (Plaque Tracker and autonomous processing in 2027; three RCTs to expand asymptomatic TAM by ~$6B to ~$11B with enrollment beginning Q4‑2026–Q1‑2027).

Strong Revenue Growth

Q2 revenue was $64.1 million, up 48% year-over-year; U.S. revenue grew 51% to $59.6 million. Management called this the fastest revenue growth in eight quarters.

Raised Full-Year Guidance

Company raised 2026 revenue guidance to $246M–$250M (40%–42% YoY growth) and increased Plaque revenue guidance to $29M–$31M and Plaque-activated accounts to ~1,250.

Margin Expansion and Gross Margin Guidance

Q2 non-GAAP gross margin reached 83.3% vs 75.6% a year ago (770 basis points improvement). Full-year non-GAAP gross margin guidance raised to ~82% and mid-term target reiterated at 85%, driven by AI efficiencies, volume leverage and higher mix of Plaque.

Improving Profitability Trajectory

Non-GAAP operating loss improved to $7.9M (versus $11.5M prior year). Non-GAAP net loss narrowed to $5.8M (−~67% vs prior-year non-GAAP net loss of $17.6M). GAAP net loss was $15.7M for the quarter.

Strong Cash Position and Path to Profitability

Ended Q2 with $246.8M in cash, cash equivalents and investments; reaffirmed plan to achieve cash flow profitability by mid-2028.

Plaque Momentum and Product Adoption

Plaque revenue was $7.8M in Q2 and management reported accelerating activations and physician utilization. Coverage ~78% and management expects continued Plaque adoption to be a near- and long-term growth driver.

FFRCT Durability and Clinical Differentiation

FFRCT utilization remained durable across accounts, benefiting from product differentiation (lesion-specific FFRCT, prospective validation) and supportive SCCT/ACC guidance that highlights clinical utility.

Clinical Evidence and Publications

Company has >625 peer-reviewed publications and >200 clinical studies; presented 8 new datasets covering >36,000 patients at SCCT; DECIDE registry showed Plaque Staging reclassified ~50% of calcium score 0 patients to higher risk.

Product and R&D Pipeline Progress

Launched Plaque Staging (validated in >23,000 patients, up to 16 years follow-up). Plaque Tracker and autonomous processing remain on track for broader rollout in 2027. PCI Navigator launched earlier in the year and is gaining traction.

Operational Metrics and Volume Expansion

Total global cases (or relevant activity) for the quarter reported at 84,491, up 74%. Management reported ongoing installed-base expansion and a record cohort of 340 accounts added in 2025 continuing to ramp.

HTFL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Nov 18, 2026	2026 (Q3)	-0.10 / -	-0.27	―
Aug 13, 2026	2026 (Q2)	-0.13 / -0.07	-0.06	-16.67% (-0.01)
May 14, 2026	2026 (Q1)	-0.19 / -0.16	-0.46	65.22% (+0.30)
Feb 12, 2026	2025 (Q4)	-0.17 / -0.12	―	―
Nov 12, 2025	2025 (Q3)	-0.24 / -0.27	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed